A national clinical trial in precision medicine - the engine pulling Sweden to the global forefront

Clinical trials translate research into practice where precision medicine through rich diagnostic data matches patients with the right treatment. How can Sweden establish a national structure for precision treatment and molecular profiling for the benefit of cancer patients?

Sweden has well-developed healthcare, high education levels within the profession, world-leading research with high trust throughout the ecosystem from patients, healthcare, and industry. In Sweden, there are challenges for the development of precision medicine in cancer: a fragmented healthcare system, challenging legal conditions for digital infrastructure for structured and automated data collection from both healthcare and research. By establishing a national trial, FOCU.SE, linked to an exploratory platform study, academia, healthcare, and industry can collaborate to develop new processes for precision diagnostics and precision medicine treatments.

Questions discussed include:

• How does Sweden compare with other countries and why is it important to invest in a national trial?

• What are the benefits for patients, healthcare, and academic research?

• Why is it important for Swedish industry?
  

Participants

• Richard Rosenquist Brandell, Professor, GMS, Karolinska Institutet, Karolinska Hospital

• Janne Lehtiö, Professor, SciLifeLab, Karolinska Institutet

• Edvard Abel, PI FOCU.SE study, Sahlgrenska University Hospital